Zimmer Holdings is a global leader in the development and manufacture of orthopaedic implants and related products, focusing on enhancing the quality of life for individuals suffering from conditions related to bones and joints. The company specializes in a wide range of surgical products and services, including joint replacement systems, trauma products, and a variety of surgical instruments. Zimmer Holdings also invests in innovative technologies and solutions to improve surgical outcomes and patient satisfaction, catering to healthcare professionals and institutions worldwide. With a commitment to advancing orthopaedic care, the company plays a crucial role in both the medical community and patient rehabilitation processes. Read More
Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid solid corporate earnings and growing signs that the Federal Reserve may be nearing another interest rate cut.
Zimmer Biomet beats Q3 earnings estimates with strong U.S. sales, driven by new products, while reaffirming 2025 guidance and narrowing growth outlook.
The financial markets are a constant ebb and flow, and recently, the tide has pulled several prominent companies down to their 52-week lows. Among them, real estate investment trust Douglas Emmett (NYSE: DEI) and medical device giant Zimmer Biomet Holdings, Inc. (NYSE: ZBH) stand out. Their recent stock performance reflects
Stay tuned for the market movements in the S&P500 index on Wednesday. Check out the gap up and gap down stocks in the S&P500 index during today's session.
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.
Medical device company Zimmer Biomet (NYSE:ZBH) met Wall Streets revenue expectations in Q3 CY2025, with sales up 9.7% year on year to $2.00 billion. Its non-GAAP profit of $1.90 per share was 2.1% above analysts’ consensus estimates.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth.
This has capped returns as the industry’s six-month gain of 13.5% has lagged the S&P 500’s 22.9% climb.
Let’s dig into the relative performance of CONMED (NYSE:CNMD) and its peers as we unravel the now-completed Q2 surgical equipment & consumables - diversified earnings season.
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Over the past six months, Zimmer Biomet’s stock price fell to $99.17. Shareholders have lost 12% of their capital, which is disappointing considering the S&P 500 has climbed by 24.7%. This might have investors contemplating their next move.
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices.
But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
Sunnyvale, CA – September 17, 2025 – Intuitive Surgical (NASDAQ: ISRG), the pioneer and global leader in robotic-assisted surgery, has once again demonstrated its formidable market position with a robust second-quarter 2025 earnings report. The company announced an impressive adjusted Earnings Per Share (EPS) of $2.19, significantly surpassing analyst expectations, coupled
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how surgical equipment & consumables - diversified stocks fared in Q2, starting with Zimmer Biomet (NYSE:ZBH).
